Regulation of myeloid-cell activation.

OA: closed
AI-generated summary by qwen3.7-flash, 2026-08-29

This review discusses the mechanisms regulating myeloid cell activation, focusing on receptors and signaling molecules that recognize pathogen- and damage-associated molecular patterns to maintain tissue homeostasis.

One-sentence paraphrase of the abstract; not a substitute for reading it. No clinical advice. How this works

AI-generated deep summary by qwen3.7-flash, 2026-08-29 · read from full text

This review examines the molecular mechanisms governing myeloid-cell activation, detailing how pathogen-associated and damage-associated molecular patterns trigger distinct inflammatory or tissue-repair programs through complex signaling cascades. The authors describe how receptor valency, kinetic segregation models, and cytoskeletal dynamics determine whether cells undergo classical pro-inflammatory activation or alternative polarization for healing. A key finding is that dysregulated myeloid activity drives various chronic diseases, with the text explicitly noting that neutrophils and macrophages contribute to endometriosis via classical inflammation and extracellular trap formation. Relevance to endometriosis: listed as one indication for GnRH antagonists, though the paper's main focus is uterine fibroids.

Read from the paper's body, not the abstract. Not a substitute for reading the paper. No clinical advice. How this works

Abstract

Myeloid cells (macrophages, monocytes, dendritic cells, and granulocytes) survey the body for signs of infection and damage and regulate tissue homeostasis, organogenesis, and immunity. They express receptors that initiate the inflammatory response, send signals that alter the vascular and cytokine milieu, and oversee the recruitment, differentiation, and activation of other myeloid and adaptive immune cells. Their activation must therefore be tightly regulated, optimized for maximal innate-immune protection with a minimum of collateral tissue damage or disorganization. In this review we discuss what it means for myeloid cells to become activated, with emphasis on the receptors and signaling molecules important for the recognition of pathogen-associated and damage-associated molecular patterns. We also outline how these signals are regulated by the steric properties of proteins, by adhesive and cytoskeletal interactions, and by negative feedback to keep inflammation in check and support healthy tissue development and homeostasis. Throughout the text we highlight recent publications and reviews and direct readers therein for a comprehensive bibliography.
Full text 18,805 characters · extracted from pmc-nxml · 8 sections · click to expand

Itam

ITAMs and hemi-ITAMs trigger myeloid-cell activation through the Src-family kinases (SFKs) and Syk kinase [ 34 ]. Unlike T cells, which can be activated by as few as 4–6 high-affinity T-cell receptor (TCR)/peptide/MHC interactions [ 35 ], most myeloid cells must interact closely with intact pathogens that ligate receptors over a large surface area to enable phagocytosis and minimize the toxic effects of inflammation, degranulation, and reactive oxygen. Macrophages, dendritic cells, and neutrophils sense the valency of receptor interactions as a proxy for the size of an interacting particle, functioning as sensors of stimulus size: high-valency ligands such as those presented by an intact pathogen (μm-scale) ligate receptors through highly multimeric cell-wall components or opsonins, initiating an antimicrobial response and inflammatory polarization. Low-valency (nm-scale) receptor ligation [ 36 ] or intracellular kinase activation alone [ 37 ] is not fully activating ( Figure 3A ). The probability of cell activation via ligation of ITAM-coupled receptors varies according to cell type, polarization, and receptor identity. Mast cells, for example, have a lower triggering threshold than macrophages [ 38 ], with the potential to signal through lower-valency ligation of FcεR [ 39 , 40 ]; mechanisms of mast-cell regulation are discussed later. One component of the ITAM particle-size sensor involves kinetic protection of ITAM/signalosome phosphorylation. Inspired by earlier studies of the T-cell synapse [ 41 ], the kinetic segregation model applied to myeloid cells postulates that the rigid/glycosylated extracellular domains of the tyrosine phosphatases CD45 and CD148 are sterically excluded from the phagocytic synapse, protecting activating phosphorylation of ITAMs, SFKs, and other molecules ( Figure 3B ). Lower-valency ITAM nanoclusters lack the requisite steric occlusion and are thus reversed before signal propagation [ 36 , 42 , 43 ]. At the other extreme, if phagocytosis is frustrated in an encounter with an overly large foreign object (e.g. fungal hypha), ITAM/hemi-ITAM signaling and subsequent production of reactive oxygen act as molecular timers, swapping classical activation for extracellular trap formation [ 44 , 45 ]. Inflammation associated with neutrophil extracellular traps (NETs) is also a hallmark of chronic inflammation, production of anti-nuclear antibodies, and autoimmune disease [ 46 ].

Itims

Negative-regulatory processes limit myeloid-cell signaling in magnitude and duration. Lipid and tyrosine phosphatases (e.g. SHIPs, SHPs) and negative-regulatory adaptor proteins (e.g. Grb2, Doks) are recruited to immunoreceptor tyrosine inhibitory motifs (ITIMs, e.g. Sirpα, PirB) [ 51 ] or monophosphorylated inhibitory ITAMs (ITAM i s) [ 52 ] to suppress inflammatory signaling ( Figure 3C ). Activated SFKs within receptor complexes also phosphorylate and activate Cbl-family E3 ubiquitin ligases, which then monoubiquitinate or polyubiquitinate nearby targets. Ubiquitin-modification of signaling components may directly block their activity, flag them for degradation, or trigger receptor internalization [ 53 ]. SFK-mediated phosphorylation and activation of c-Cbl also feeds back to downregulate all the SFKs via a slow (half-life 10+ min) process of polyubiquitination and degradation [ 37 ]. In addition to its more promiscuous negative-regulatory functions, c-Cbl mediates the rapid, selective degradation of the SFK LynA, the longer of two Lyn splice variants [ 34 , 37 , 38 ]. In macrophages, phosphorylation of LynA at tyrosine 32 (pY32) [ 38 , 54 ] targets LynA for rapid degradation (half-life 1 min), causing a signaling blockade downstream of PLCγ and PI3K [ 37 ] ( Figure 3D ). LynA and c-Cbl expression are regulated by cell type [ 38 ] and inflammatory polarization [ 37 ], lending context specificity to this signaling checkpoint and regulating each cell’s sensitivity to activation. For example, in resting macrophages high expression of c-Cbl and low expression of LynA block cell activation in the absence of low-valency receptor ligation. Inflammatory polarization with IFN-γ upregulates LynA, overcoming the signaling checkpoint and sensitizing macrophage activation [ 37 ]. Mast cells, in contrast, express little c-Cbl, increasing steady-state accumulation of LynA protein and sustaining LynA activation during signaling [ 38 ]. This sensitivity to SFK-mediated signaling may underlie the exquisite sensitivity of mast-cell FcεRs to low-valency receptor ligands [ 39 , 40 ]. The cell- and environment-specific expression level of LynA and c-Cbl therefore comprise a coordinated signaling rheostat that tunes the intensity and longevity of the LynA response in a cell-type- and environment-specific manner. In contrast, the shorter splice form of Lyn kinase, LynB, has the dominant role in preventing autoimmune disease. In a recent study using CRISPR/Cas9-generated LynA and LynB isoform-specific knockout mice [ 55 ], LynB knockout mice preferentially develop the lupus disorder observed in total Lyn knockout mice [ 56 ]. Together, these observations suggest that the dual positive and negative functions of Lyn kinase shared unequally by the two splice forms, LynA and LynB, respectively [ 34 , 37 , 38 , 55 ].

Spotlight

Macrophages are particularly plastic cells, with myriad polarization and tissue-specific states. Their sensitivity to environmental cues, which induce a spectrum of substates with tissue-remodeling ( Figure 4A ) and/or inflammatory ( Figure 4B ) functionalities, is reflected in their many roles in systemic and tissue-specific disease. In autoimmune disease, macrophages promote immune-cell infiltration, release inflammatory cytokines (e.g. TNF, IL-1, IL-6) and drive a feedback cycle of chronic inflammation ( Figure 4C ). In macrophage activation syndrome (MAS), for example, systemic overproduction of IFN-γ [ 57 ], chronic elevation of IL-18 [ 58 ], and/or sustained activation of TLRs [ 59 ] drives excessive and sustained release of inflammatory cytokines and dysregulates phagocytosis [ 60 ]. Macrophages are among the cells found in the presumably sterile synovia of RA and juvenile idiopathic arthritis (JIA) patients [ 61 ]. In atherosclerosis, low-density lipoprotein induces foamy macrophage differentiation, dysregulation, and necrosis [ 62 ]. Proliferating intima-resident macrophages are then gradually replaced by infiltrating monocytes; a combination of inflammatory and tissue-resident functions then drives plaque progression [ 63 ]. Chronic obstructive pulmonary disorder (COPD) and acute respiratory distress syndrome (ARDS) are linked to downregulation of Programmed Death Ligand (PDL) proteins in the lung, resulting in hyperactivation of alveolar macrophages [ 64 , 65 ]. Tumor cells establish a microenvironment in which the cytokine milieu may evoke tissue-remodeling as well as inflammatory functions in macrophages ( Figure 4D ), including matrix reorganization [ 66 ], support for metastasis, and T-cell suppression [ 67 , 68 ]. Deleterious activation of macrophages by abnormal production or responsiveness to either pro- or anti-inflammatory stimuli breaks tissue homeostasis and promotes disease. The developmental origins of tissue macrophages add another layer of pathway bias and functional heterogeneity. Tissues are initially seeded by yolk-sac progenitors, which give rise to resident macrophages in the brain (microglia), liver (Kupffer cells), and other sites [ 69 – 71 ]. A second wave of hematopoiesis from the fetal liver gives rise to other tissue macrophages (e.g. intestine, lung) and circulating monocytes [ 70 ], which may also repopulate tissues [ 72 ]. Tissue signals imprint newly differentiated macrophages with site-specific activation profiles [ 73 ], restraining the inflammatory response during routine clearance of apoptotic cells [ 74 ]. However, these signals become dysregulated when embryonically derived macrophages drive fibrosis and cancer [ 75 ]. Recruitment and replacement of tissue-resident macrophages following tissue injury can also confer protection from bacterial infections, as newly differentiated macrophages may retain epigenetic traits from their monocyte precursors that facilitate rapid production of cytokines after a bacterial encounter [ 76 ]. Tissues with resident macrophages “paralyzed” by previous pathogen exposure [ 77 ] are thus supplemented with new, potentially pro-inflammatory macrophages. However, unrestrained inflammation, as in malarial infection [ 59 ], can drive monocyte differentiation into red-blood cell phagocytes that drive pathologic anemia. While the seeding of tissues by circulating monocytes and macrophage programming by the tissue microenvironment add flexibility to tissue homeostasis, both processes may be dysregulated in disease.

Concluding

Myeloid cells are highly diverse, with a complex blend of overlapping abilities and cell-specific functions. Regulation of oxidative killing, phagocytosis, degranulation, and cytokine secretion is complex and context-specific. Nevertheless, patterns of regulatory modalities emerge as general principles: polarization by cytokines and tissue signals, receptor diffusion barriers, and intracellular regulation of receptor activation, with the SFKs and Lyn standing out as a central regulatory node. Crosstalk between receptor pathways confers higher-order regulation, sensitizing or frustrating interacting cascades. Diseases such as lupus and cancer be accompanied by the subversion of these regulatory features. Mechanistic research defining how myeloid cells integrate positive- and negative-regulatory signals from tissues, immune-cells, and multiple receptors to bias or sensitize their myriad signaling pathways will be the key to understanding the processes of homeostasis and disease and modulating myeloid-cell function with ever-increasing specificity to the benefit of research and therapeutics.

Regulation

Activation of myeloid cells by pathogen-associated ligands (via Dectin-1) and antibodies (via FcRs) is regulated by constraints on lateral diffusion. Hyaluronan fences interact with CD44 pickets, anchored intracellularly to cortical actin filaments. While diffusion in two dimensions within the resulting actin corrals is relatively unrestricted, diffusion between corrals is limited. Spontaneous formation of higher-order receptor clusters is blocked, protecting against amplification of spurious or stochastic initiating signals [ 47 ]. With sufficiently robust receptor activation (straddling multiple corrals and/or with high-affinity/low-off-rate ligand-receptor interactions), the activities of SFKs and Syk initiate remodeling of cortical actin, reorganizing corrals, relieving constraints on lateral diffusion, enabling higher-order receptor clustering, and forming a phagocytic cup [ 48 ]. Integrins contribute to receptor clustering and activation by stabilizing interactions between myeloid and target cells via interactions with complement and cell-wall β-glucans. This close-contact region favors formation of new interactions and rebinding of high-off-rate interacting partners, so the two cell surfaces zip together. Positive feedback through integrins during phagocytosis enhances receptor binding and kinetic segregation [ 42 ]. This is especially important when a myeloid cell interacts with non-diffusible components of a pathogen cell wall: a μm-scale cluster of ITAM-coupled receptors need not be continuous but may be punctate on the nanoscale, with integrins mediating interstitial interactions. Integrin-triggered signaling can also potentiate activation of other receptors, such as TLRs [ 49 , 50 ].

Alternative

Myeloid cells can be alternatively polarized to repair or remodel tissue, suppress or end the antimicrobial response, and antagonize the effects of inflammatory cytokines [ 4 ]. The combined effects of tissue- and context-specific signals on different types of myeloid cells, however, are complex and defy simple categorization. As with inflammatory polarization, immunosuppressive or tissue-remodeling polarization may be effected through multiple receptor pathways [ 4 ] ( Figure 2A ). The effects of these signals depend on receptor availability, cell type, and other factors in the tissue. IL-4 and IL-13, for instance, can trigger anti-inflammatory signaling, leading to reduced production of IL-1β and TNF by macrophages, but they are also components of type 2 inflammation, driving host defense against parasites. Detection of neutrophil apoptotic cell debris can comprise a second signal to induce a tissue-repair polarization in macrophages during wound healing [ 26 , 27 ]. The effects of inflammatory and tissue-remodeling polarization may be shared or distinct. For instance, either IFN-γ or IL-4 increases upstream and downstream kinase phosphorylation in macrophages responding to fungal cell wall [ 12 ], but these cytokines have different functional outcomes with respect to phagocytosis and transcription—how specificity is achieved is complex [ 28 ] and incompletely understood. Combinatorial effects of tissue- and danger-specific inputs yield a spectrum of polarization states. Via coordinated changes in receptor, effector, and negative-regulator expression, initial triggering and signal amplitudes are sensitized or desensitized to bias pathway activation. For example, the activation of T-cells by dendritic cells via antigen presentation, induces an increase in expression of ligands for Tyro/Axl/Mer (TAM-family) receptor tyrosine kinases on myeloid cells. Ligation of these kinases then restrains inflammatory activation of dendritic cells [ 29 ]. Polarization also time-regulates the inflammatory response, mediating shifts from anti-pathogen to tissue-repair functionality ( Figure 2B ). While simultaneous detection of intact pathogen and apoptosis mediates an antimicrobial response [ 30 , 31 ], the detection only of apoptosis and tissue signals such as IL-4 induces healing and inflammation resolution [ 26 ]. Therefore, a time- and environment-dependent shift from inflammatory to alternative polarization after a tissue insult ensures that pathogen elimination is accompanied by repair of damaged tissue and return to homeostasis [ 32 , 33 ].

Inflammatory

Tissue- and perturbation-specific signals alter gene transcription to bias activation of specific signaling pathways, immediate cellular functions, and transcriptional programs [ 8 , 9 ]. For instance, macrophage exposure to IFN-γ, Granulocyte-Macrophage Colony-Stimulating Factor (GM-CSF), or Tumor Necrosis Factor (TNF) increases subsequent sensitivity to pathogens and alters myeloid-cell and lymphocyte recruitment, differentiation, polarization, and activation [ 10 ]; C-C motif chemokine ligand (CCL)2 and macrophage inflammatory protein (MIP)-1 induce similar responses through G-Protein-Coupled Receptors (GPCRs) [ 11 ] ( Figure 1B , right). PAMPs and DAMPs are dually activating and polarizing. For example, ligation of the hemi-ITAM-containing receptor Dectin-1 by cell-wall β-glucans induces phagocytosis and TNF production (acute, classical activation) [ 12 ], and increases transcription of inducible nitric oxide synthase (iNos) and other pro-inflammatory factors to increase the sensitivity to future activation [ 13 ]. Due to their near-ubiquity and myriad functions, inappropriately activated myeloid cells underlie drive many pathologies ( Figure 1C ). Chronic inflammatory activation, often resulting from a feedback cycle of increased signaling amplitude downstream of ITAMs [ 14 ], TLRs [ 15 ], or CRs [ 16 ] and increased myeloid-cell infiltration of tissues, drives autoimmune, allergic, and other inflammatory diseases [ 17 – 19 ]. Megakaryocytes, platelets, and neutrophils have been particularly highlighted in the recent literature. Defects in megakaryocyte autophagy reduce platelet function in immune thrombocytopenic purpura [ 20 ]. Megakaryocytes can also mediate inflammatory exchange between neutrophils and platelets through emperipolesis, a cell-engulfment process [ 21 ]. Neutrophils and macrophages drive diseases such as RA and endometriosis via classical inflammatory activation and by the formation of extracellular traps. Dysregulation of these myeloid cells also drives the cytokine storm and respiratory disruption that accompany the most severe forms of sepsis [ 22 ], influenza [ 23 ], and COVID-19 [ 24 , 25 ].

Introduction

Myeloid cells populate nearly every space in the body. They are first responders, sensing infection and tissue damage, killing pathogens, and regulating innate and adaptive immune functions. As part of this interplay, they direct immune-cell recruitment and differentiation, mediate antigen presentation, and control the amplitude and kinetics of the inflammatory response [ 1 ]. Myeloid cells also have critical roles in tissue architecture, remodeling extracellular matrix [ 2 ], guiding organ development [ 3 ], and directing vascularization [ 4 ] ( Figure 1A ). Mechanisms regulating the quality, strength, and duration of myeloid-cell activation are therefore critically important. Due to their pleiotropic responsiveness to a vast array of stimuli, the spectrum of “myeloid-cell activation” encompasses many distinct functional programs. Activation is broadly defined as a response to pathogen- or damage-associated molecular patterns (PAMPS, DAMPS), opsonized particles, or cytokines that results in an acute functional outcome. Generally, receptor ligation triggers a kinase cascade (within seconds); rearrangement of the actin cytoskeleton, phagocytosis, degranulation, and release of reactive oxygen, nitric, oxide, calcium, and other second-messengers (within minutes); and expression/secretion of cytokines and polarization-specific proteins (within hours). “Classical” pro-inflammatory activation occurs via Toll-like Receptors (TLRs), Complement Receptors (CRs), intracellular Immunoreceptor Tyrosine-based Activation Motifs (ITAMs), and receptors for cytokines such as interferon (IFN)-γ ( Figure 1B , left). Inflammatory responses have distinct features determined by the myeloid-cell subtype, the tissue milieu, and the receptor ligands presented by the pathogen. For example, gram-positive bacteria activate TLR2 on macrophages, whereas gram-negative bacteria activate TLR2+TLR4, producing tailored inflammatory responses with distinct cytokine profiles [ 5 ]. “Alternative” activation is defined as the myeloid response to interleukins (ILs) (e.g. IL-4, −13, −5, −33) that induce anti-helminth or tissue-repair functions, depending on other environmental cues [ 4 ]. The functional results of these cues vary but include metabolic changes that promote oxidative phosphorylation in macrophages [ 6 ], degranulation of eosinophils and mast cells, and tissue reorganization [ 7 ].

Text is read by the "Ask this paper" AI Q&A widget below. Extraction quality varies by source — PMC NXML preserves structure cleanly, OA-HTML may include some navigation residue, and OA-PDF can have broken hyphenation. The publisher copy (via DOI) is the canonical version.

My notes (saved in your browser only)

Ask this paper AI returns verbatim quotes from the full text · source: pmc-nxml

Answers must be backed by verbatim quotes from this paper's full text. Hallucinated quotes are dropped automatically; if no verbatim passage answers the question, we say so. How this works

Citation neighborhood (no data yet)

We don't have any in-corpus citations linked to this paper yet. The paper's references may be in our DB but unresolved to ``paper_id`` (resolution happens at ingest when the cited DOI matches a row we already have). Run the cross-source citation reconcile pass to retry.

Source provenance

europepmc
last seen: 2026-09-06T09:34:12.023084+00:00